Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Healthtrust
Fuji
Covington
Daiichi Sankyo
UBS
QuintilesIMS
Merck
Julphar
Chinese Patent Office

Generated: October 18, 2017

DrugPatentWatch Database Preview

Degarelix acetate - Generic Drug Details

« Back to Dashboard

What are the generic sources for degarelix acetate and what is the scope of degarelix acetate freedom to operate?

Degarelix acetate
is the generic ingredient in one branded drug marketed by Ferring and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Degarelix acetate has one hundred and twenty-two patent family members in thirty-six countries and eleven supplementary protection certificates in ten countries.

One supplier is listed for this compound.

Summary for Generic Name: degarelix acetate

US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list15
Clinical Trials: see list989
Patent Applications: see list11
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:degarelix acetate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► Subscribe ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► SubscribeYY ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-001Dec 24, 2008RXYesNo► Subscribe► SubscribeYY ► Subscribe
Ferring
FIRMAGON
degarelix acetate
POWDER;SUBCUTANEOUS022201-002Dec 24, 2008RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: degarelix acetate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,214,798 GnRH antagonists being modified in positions 5 and 6► Subscribe
8,841,081Method of treating metastatic stage prostate cancer► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: degarelix acetate

Country Document Number Estimated Expiration
Portugal2249859► Subscribe
Portugal2650012► Subscribe
Norway2009016► Subscribe
Australia2009213751► Subscribe
China1259959► Subscribe
Denmark2249859► Subscribe
Slovakia285381► Subscribe
Japan5924866► Subscribe
Japan5876652► Subscribe
Japan3645255► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: DEGARELIX ACETATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2Finland► Subscribe
C/GB09/028United Kingdom► SubscribePRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
585Luxembourg► SubscribePRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
C0028France► SubscribePRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
2009005,C1003774Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
2009005Lithuania► SubscribePRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
C020/2009Ireland► SubscribeSPC020/2009: 20091119, EXPIRES: 20230412
2009 00022Denmark► Subscribe
2009000033Germany► SubscribePRODUCT NAME: DEGARELIX, GGF. IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES DAVON, WIE DEM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001-002 20090217
1003774/01Switzerland► SubscribePRODUCT NAME: DEGARELIX; REGISTRATION NUMBER/DATE: SWISSMEDIC 59455 12.02.2010
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Citi
Argus Health
McKinsey
Healthtrust
US Department of Justice
US Army
Fuji
Baxter
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot